SEARCH:   Advanced

Blood, 1 September 2006, Vol. 108, No. 5, pp. 1724-1732. Prepublished online as a Blood First Edition Paper on May 16, 2006; DOI 10.1182/blood-2006-03-009910. This Article Full Text (PDF) Supplemental Data All Versions of this Article: blood-2006-03-009910v1 108/5/1724    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hanamura, I. Articles by Shaughnessy Jr., J. D Search for Related Content PubMed PubMed Citation Articles by Hanamura, I. Articles by Shaughnessy Jr., J. D Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 15, 2006 Accepted April 25, 2006 Frequent gain of chromosome band 1q21 in plasma cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem cell transplantation Ichiro Hanamura, James P Stewart, Yongsheng Huang, Fenghuang Zhan, Madhumita Santra, Jeffery R Sawyer, Klaus Hollmig, Maurizio Zangarri, Mauricio Pineda-Roman, Frits van Rhee, Federica Cavall, Bart Burington, John Crowley, Guido Tricot, Bart Barlogie, and John D Shaughnessy Jr.* Donna D. and Donald M. Lambert Lab., University of Arkansas for Medical Sciences, Little Rock,AR,USA University of Arkansas for the Medical Sciences University of Arkansas for Medical Sciences Cancer Research and Biostatistics, Seattle, WA, USA * Corresponding author; email: shaughnessyjohn{at}uams.edu. Using fluorescence in situ hybridization we investigated amplification of chromosome band 1q21 (Amp1q21) in over 500 untreated patients with monoclonal gammopathy of undetermined significance (MGUS, n=14), smoldering multiple myeloma (SMM, n=31) and newly diagnosed MM (n=479) as well as 45 relapsed MM. The frequency of Amp1q21 was 0% in MGUS, 45% in SMM, 43% in newly diagnosed MM and 72% in relapsed MM (newly diagnosed vs. relapsed MM, P<0.0001). Amp1q21 was detected in 10 of 12 patients who evolved to active MM compared to 4 of 19 who remained SMM (P<0.001). Newly diagnosed MM with Amp1q21 had inferior 5- year event- free/overall survival compared with those lacking Amp1q21 (38%/52% vs. 62%/78%, both, P<0.0001). Thalidomide improved 5-year EFS in patients lacking Amp1q21 but not in those with Amp1q21, P=0.0044). Multivariate analysis including other major predictors revealed that Amp1q21 was an independent poor prognostic factor. Relapsed patients who had Amp1q21 at relapse had inferior 5-year post-relapse survival compared with those lacking Amp1q21 at relapse (15% vs. 53%, P=0.0271). The proportion of cells with Amp1q21 and the copy number of 1q21 tended to increase at relapse compared with diagnosis. Our data suggest that Amp1q21 is associated with both disease progression and poor prognosis. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Gain of 1q21 in multiple myeloma: from bad to worse? Pieter Sonneveld Blood 2006 108: 1426-1427. [Full Text] [PDF] This article has been cited by other articles: S. Blotta, P. Tassone, R. H. Prabhala, P. Tagliaferri, D. Cervi, S. Amin, J. Jakubikova, Y.-T. Tai, K. Podar, C. S. Mitsiades, et al. Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance Blood, October 8, 2009; 114(15): 3276 - 3284. [Abstract] [Full Text] [PDF] H. Avet-Loiseau, C. Li, F. Magrangeas, W. Gouraud, C. Charbonnel, J.-L. Harousseau, M. Attal, G. Marit, C. Mathiot, T. Facon, et al. Prognostic Significance of Copy-Number Alterations in Multiple Myeloma J. Clin. Oncol., September 20, 2009; 27(27): 4585 - 4590. [Abstract] [Full Text] [PDF] L. Chiecchio, G. P. Dagrada, R. K.M. Protheroe, D. M. Stockley, A. G. Smith, K. H. Orchard, N. C.P. Cross, C. J. Harrison, F. M. Ross, and on behalf of the UK Myeloma Forum Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case Haematologica, July 1, 2009; 94(7): 1024 - 1028. [Abstract] [Full Text] [PDF] D. Hose, T. Reme, T. Meissner, J. Moreaux, A. Seckinger, J. Lewis, V. Benes, A. Benner, M. Hundemer, T. Hielscher, et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma Blood, April 30, 2009; 113(18): 4331 - 4340. [Abstract] [Full Text] [PDF] E. Spanoudakis, M. Hu, K. Naresh, E. Terpos, V. Melo, A. Reid, I. Kotsianidis, S. Abdalla, A. Rahemtulla, and A. Karadimitris Regulation of multiple myeloma survival and progression by CD1d Blood, March 12, 2009; 113(11): 2498 - 2507. [Abstract] [Full Text] [PDF] W. Xiong, X. Wu, S. Starnes, S. K. Johnson, J. Haessler, S. Wang, L. Chen, B. Barlogie, J. D. Shaughnessy Jr, and F. Zhan An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma Blood, November 15, 2008; 112(10): 4235 - 4246. [Abstract] [Full Text] [PDF] T. Bochtler, U. Hegenbart, F. W. Cremer, C. Heiss, A. Benner, D. Hose, M. Moos, J. Bila, C. R. Bartram, A. D. Ho, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability Blood, May 1, 2008; 111(9): 4700 - 4705. [Abstract] [Full Text] [PDF] E. Tian, T. H. Landowski, O. W. Stephens, S. Yaccoby, B. Barlogie, and J. D. Shaughnessy Jr. Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma Mol. Cancer Ther., March 1, 2008; 7(3): 500 - 509. [Abstract] [Full Text] [PDF] K. Mahtouk, D. Hose, J. De Vos, J. Moreaux, M. Jourdan, J. F. Rossi, T. Reme, H. Goldschmidt, and B. Klein Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications Clin. Cancer Res., December 15, 2007; 13(24): 7289 - 7295. [Abstract] [Full Text] [PDF] H. K. Prasad, F. Zhan, J. Shaughnessy, D. Focosi, A. T. Andrews, R. A. Kyle, and S. V. Rajkumar Smoldering Multiple Myeloma N. Engl. J. Med., September 6, 2007; 357(10): 1048 - 1050. [Full Text] [PDF] J. A. Katzel, P. Hari, and D. H. Vesole Multiple Myeloma: Charging Toward a Bright Future CA Cancer J Clin, September 1, 2007; 57(5): 301 - 318. [Abstract] [Full Text] [PDF] P. Sonneveld, B. van der Holt, C. M. Segeren, E. Vellenga, A. J. Croockewit, G. E.G. Verhoef, J. J. Cornelissen, M. R. Schaafsma, M. H.J. van Oers, P. W. Wijermans, et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial Haematologica, July 1, 2007; 92(7): 928 - 935. [Abstract] [Full Text] [PDF] F. Zhan, S. Colla, X. Wu, B. Chen, J. P. Stewart, W. M. Kuehl, B. Barlogie, and J. D. Shaughnessy Jr CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms Blood, June 1, 2007; 109(11): 4995 - 5001. [Abstract] [Full Text] [PDF] F. Zhan, B. Barlogie, V. Arzoumanian, Y. Huang, D. R. Williams, K. Hollmig, M. Pineda-Roman, G. Tricot, F. van Rhee, M. Zangari, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis Blood, February 15, 2007; 109(4): 1692 - 1700. [Abstract] [Full Text] [PDF] F. Zhan, Y. Huang, S. Colla, J. P. Stewart, I. Hanamura, S. Gupta, J. Epstein, S. Yaccoby, J. Sawyer, B. Burington, et al. The molecular classification of multiple myeloma Blood, September 15, 2006; 108(6): 2020 - 2028. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020